Drugs / GSK2321138A
last change Mar 2015 re-read 2 minutes ago

GSK2321138A

Vaccine

Developed for
influenza
Investigated by
GlaxoSmithKline

Trials 6 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 22 trials
Phase 2 NCT01195779 Sep 2010 → Mar 2011 influenza GlaxoSmithKline Terminated No outcome recorded
Phase 2 NCT00985790 Oct 2009 → May 2010 influenza GlaxoSmithKline Completed No outcome recorded
Phase 34 trials
Phase 3 NCT01954251 Oct 2013 → Jun 2014 herpes zoster GlaxoSmithKline Completed No outcome recorded
Phase 3 NCT01439360 Oct 2011 → Oct 2014 influenza GlaxoSmithKline Completed No outcome recorded
Phase 3 NCT01204671 Oct 2010 → Jun 2011 influenza GlaxoSmithKline Completed No outcome recorded
Phase 3 NCT01196988 Oct 2010 → Jun 2011 influenza GlaxoSmithKline Completed No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 6 sources stand behind the page.

FieldValueCited text
Known as GSK2321138A ClinicalTrials.gov intervention name — accepted as the source's own label NCT01439360
5

NCT00985790

NCT01195779

NCT01204671

NCT01954251

NCT01196988

Known as Flu D-QIV “Quadrivalent seasonal influenza vaccine(Flu D-QIV) GSK2321138A” NCT01439360
Known as Influsplit Tetra vaccine “Subjects received 1 or 2 doses of candidate influenza Influsplit™ Tetra vaccine (GSK2321138A).” NCT01439360
Modality Vaccine “GSK2321138A vaccineNCT00985790
Route Intramuscular “The GSK2321138A vaccine was administered intramuscularly in the deltoid of the right arm.” NCT00985790